Compare BFC & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BFC | HRMY |
|---|---|---|
| Founded | 1894 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.6B |
| IPO Year | 2018 | 2020 |
| Metric | BFC | HRMY |
|---|---|---|
| Price | $132.21 | $27.44 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 10 |
| Target Price | ★ $150.00 | $46.70 |
| AVG Volume (30 Days) | 75.8K | ★ 683.7K |
| Earning Date | 04-14-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.51% | N/A |
| EPS Growth | ★ 11.23 | 7.97 |
| EPS | ★ 7.23 | 2.71 |
| Revenue | N/A | ★ $868,453,000.00 |
| Revenue This Year | $58.67 | $19.75 |
| Revenue Next Year | $2.01 | $12.88 |
| P/E Ratio | $18.31 | ★ $10.18 |
| Revenue Growth | N/A | ★ 21.51 |
| 52 Week Low | $93.00 | $25.52 |
| 52 Week High | $153.00 | $40.87 |
| Indicator | BFC | HRMY |
|---|---|---|
| Relative Strength Index (RSI) | 41.48 | 34.69 |
| Support Level | $118.71 | $25.71 |
| Resistance Level | $133.35 | $28.99 |
| Average True Range (ATR) | 4.11 | 0.71 |
| MACD | -0.27 | 0.22 |
| Stochastic Oscillator | 20.89 | 31.70 |
Bank First Corp is a United States-based company engaged in providing financial services provides a full range of consumer and commercial financial institution services to individuals and businesses including retail and commercial banking in Wisconsin. These services include credit cards; secured and unsecured consumer, commercial, and real estate loans; demand, time, and savings deposits; and ATM processing. The Corporation also offers a full line of insurance services and checking accounts, savings accounts, money market accounts, cash management accounts, certificates of deposit, commercial and industrial loans, commercial real estate loans, construction and development loans, residential mortgages, consumer loans, credit cards, online banking, telephone banking, and mobile banking.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.